NO942660L - Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier - Google Patents

Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier

Info

Publication number
NO942660L
NO942660L NO942660A NO942660A NO942660L NO 942660 L NO942660 L NO 942660L NO 942660 A NO942660 A NO 942660A NO 942660 A NO942660 A NO 942660A NO 942660 L NO942660 L NO 942660L
Authority
NO
Norway
Prior art keywords
cells
cytolytic
precursors
pbmcs
characteristic
Prior art date
Application number
NO942660A
Other languages
English (en)
Norwegian (no)
Other versions
NO942660D0 (no
Inventor
Pierre G Coulie
Thierry Boon
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO942660D0 publication Critical patent/NO942660D0/no
Publication of NO942660L publication Critical patent/NO942660L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO942660A 1992-01-21 1994-07-15 Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier NO942660L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82393392A 1992-01-21 1992-01-21
PCT/US1993/000083 WO1993014189A1 (en) 1992-01-21 1993-01-07 Method for determining cytolytic t cell precursors

Publications (2)

Publication Number Publication Date
NO942660D0 NO942660D0 (no) 1994-07-15
NO942660L true NO942660L (no) 1994-09-16

Family

ID=25240169

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942660A NO942660L (no) 1992-01-21 1994-07-15 Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier

Country Status (8)

Country Link
EP (1) EP0624189A4 (ja)
JP (1) JPH07503134A (ja)
KR (1) KR950700402A (ja)
AU (1) AU3435293A (ja)
CA (1) CA2128424A1 (ja)
FI (1) FI943422A0 (ja)
NO (1) NO942660L (ja)
WO (1) WO1993014189A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664560B2 (en) * 1991-05-23 1995-11-23 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6352826B1 (en) 1991-11-25 2002-03-05 Yoreh Biotechnologies, Ltd. Method and kit for the detection of retroviral specific antibodies in seronegative individuals
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
EP0756604A1 (en) 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
CA2243235C (en) * 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
JP2001504233A (ja) * 1996-11-22 2001-03-27 シルーヴ メディカル テクノロジーズ リミテッド 癌を有する被験者の早期検出のための全血/マイトジェンアッセイおよびキット

Also Published As

Publication number Publication date
EP0624189A1 (en) 1994-11-17
KR950700402A (ko) 1995-01-16
NO942660D0 (no) 1994-07-15
CA2128424A1 (en) 1993-07-22
EP0624189A4 (en) 1995-05-17
FI943422A7 (fi) 1994-07-19
FI943422L (fi) 1994-07-19
AU3435293A (en) 1993-08-03
WO1993014189A1 (en) 1993-07-22
JPH07503134A (ja) 1995-04-06
FI943422A0 (fi) 1994-07-19

Similar Documents

Publication Publication Date Title
NO861104L (no) Fremgangsmaate for bestemmelse av monomersekvensen i molekyler.
NO942660L (no) Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier
DK122184D0 (da) Indretning til mikrobiologisk afproevning
DK393886A (da) Monoklone antistoffer og antigen for humane ikke-smaacellede lungecarcinomer
ES511797A0 (es) "metodo para ensayar reacciones antigeno-anticuerpo".
EP0140379A3 (en) Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
EP0247730A3 (en) Antibodies, their preparation and use and products containing them
NO932320D0 (no) Fremgangsmaate for paavisning av en analytt i en proeve og et utstyrsett for denne
DK98187A (da) Monoklonale antistoffer og antigen for human ikke-smaacellet lungecarcinoma og visse andre typer human carcinoma
DK199779A (da) Renset antigen til undersoegelse for neisseria gonorrhoeae antistoffer
DE2965570D1 (en) Method for the detection and/or determination of an antigen specific immunoglobulin, immuno-reagents to be used in said method and test kit for said determination
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
DK344579A (da) Diagnostisk middel og fremgangsmaade til paavisning af antimitochondriale eller antinukleaere antistoffer
NO172910C (no) Fremgangsmaate for utproeving av en proeve av celler med hensyn til naervaer av celleoverflateantigen
DK247486D0 (da) Nonoklone antistoffer og deres anvendelse
ES8606948A1 (es) Mejoras intruducidas en un ensayo para determinar un antigeno bacteriano en una muestra de ensayo
DK412184A (da) Molekylaert klonet diagnostisk produkt og fremgangsmaade til in vitro detektion af antistof eller antigen
ATE135468T1 (de) Vorprüfung von prostatakrebs durch serum prostatischen spezifischen antigen
NO880835L (no) Fremgangsmaate og anordning for kvalitativ og/eller kvantitativ analyse av antigener, antistoffer, mikroorganismer eller andre celler.
ES2187639T3 (es) Analisis de fijacion competitiva para antigenos plaquetarios.
EP0248147A3 (en) Method of determining the presence of cancer cells
DK0824696T3 (da) Fremgangsmåde og kit til at forudsige den terapeutiske reaktion på et medikament mod en malign tumor
DK98692A (da) Monoklonalt antistof og fremgangsmaade til fremstilling deraf, hybridoma, som producerer det monoklonale antistof, og proeve for tumorcellefoelsomhed under anvendelse af det monoklonale antistof
AU538833B2 (en) Method of diagnosing arterosclerosis
JPS56150356A (en) Immunologic measuring method